FDA
-
-
-
-
-
-
-
Lake Street on Monopar Therapeutics (MNPR): attractive risk/reward entry point
-
-
-
-
-
-
-
Monopar appoints Susan Rodriguez as chief commercial officer
-
-
-
-
-
-
-
Jones Trading Assumes Monopar Therapeutics (MNPR) at Buy, PT $130
-
-
-
-
-
-
-
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
-
-
-
-
-
-
-
Monopar Therapeutics (MNPR) Phase 2b/3 VOICE Trial of Validive Did Not Meet the Pre-Defined Threshold for Efficacy
-
-
-
-
-
-
-
Monopar Therapeutics (MNPR) Issues Update on Clinical and Preclinical Programs
-
-
-
-
-
-
-
Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

